MMP2 and central nervous system cancer: MMP2 and, to a lesser extent, MMP9 were predictive of response, PFS, and OS in two independent small cohorts of patients with recurrent high-grade gliomas treated with bevacizumab, but not in a third cohort of patients treated by chemotherapy only [6].